FOR RESEARCHERS
RUNX1 Research Grants
Applications are now being accepted for the 2026 RRP-ALSF Research Accelerating RUNX1 Exploration (RARE) Grant
The RARE Grant supports research focused on identifying druggable oncogenic pathways and advancing cancer interception and prevention strategies toward clinical application. Funded projects will demonstrate clear potential to benefit patients and families affected by RUNX1-FPD.
Application Deadline: Thursday, December 11, 2025 before 8 p.m. ET
RRP Cancer Interception/ Prevention Research Roadmap
Our roadmap is simple. We only invest in research that brings us one step closer to our end goal. We understand that discovering medicines requires the right tools (i.e. disease models and laboratory reagents) and the right datasets (i.e. patient clinical and genomic data, as well as patient biospecimens). We have defined 4 rational therapeutic approaches to preventing blood cancer:
1) selectively targeting precancerous cells;
2) increasing RUNX1 activity;
3) decreasing cancer-causing inflammation;
4) fixing or replacing RUNX1-mutated cells using cell or gene therapy.
